Datafarm Announces the Release of Web-Based eCTD Viewer
Datafarm announces the release of a simple and cost effective Web-based eCTD viewer for companies of all sizes.
Philadelphia, 19 June 2006-Datafarm, the leading provider of electronic regulatory submission solutions, today announced the availability of eCTDViewer® Web Edition Version 3.0. This Web-based eCTD viewing solution includes support for all recent eCTD specifications and guidelines published by ICH, FDA, EMEA (including the most recent v1.2 specifications), Japan, Health Canada and Taiwanese agencies. This business tool offers zero desktop footprint and is designed meet the needs of companies of all sizes.
eCTDViewer Web Edition is built upon recognized technology standards such as HTML, XML, and JAVA. This combination of cross-platform technologies makes the application easy to deploy on both Windows and Linux servers, and allows it to support multiple application servers such as BEA WebLogic and Apache Tomcat. By using this standards-based approach, Datafarm has made it possible for any organization, regardless of size, to seamlessly incorporate eCTDViewer® Web Edition into their existing environment.
Datafarm's eCTD suite of applications includes eCTDBuilder®, used for submission compilation, and eCTDViewer® for submission review and paper dossier creation. This suite is currently used by over 40 companies in the US, EU, Canada and Japan who have successfully submitted over 800 submissions to the regulatory authorities.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
